Evolus Inc. (EOLS)
NASDAQ: EOLS
· Real-Time Price · USD
11.65
-0.36 (-3.00%)
At close: May 06, 2025, 3:59 PM
12.52
7.47%
Pre-market: May 07, 2025, 04:45 AM EDT
-3.00% (1D)
| Bid | 11.5 |
| Market Cap | 751.08M |
| Revenue (ttm) | 266.27M |
| Net Income (ttm) | -50.42M |
| EPS (ttm) | -0.81 |
| PE Ratio (ttm) | -14.38 |
| Forward PE | 17.65 |
| Analyst | Buy |
| Ask | 14.11 |
| Volume | 770,701 |
| Avg. Volume (20D) | 838,238 |
| Open | 11.67 |
| Previous Close | 12.01 |
| Day's Range | 11.62 - 12.04 |
| 52-Week Range | 8.67 - 17.82 |
| Beta | 1.12 |
About EOLS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EOLS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EOLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Evolus Inc. is scheduled to release its earnings on May 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.47%
Evolus shares are trading higher after the company...
Unlock content with
Pro Subscription
3 months ago
+28.26%
Evolus shares are trading higher after the company announced it expects FDA approval for Evolysse gels within 90 days and is eyeing a Q2 2025 rollout in the US. Additionally, the company reported Q4 and FY24 revenue results and provided FY25 guidance.
2 weeks ago · businesswire.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April ...
